Psychedeic-Chronicle-Logo

Suggestions

  • Psychedelic News
  • DMT
  • Ketamine
  • Mescaline
  • Psilocybin
  • CEO INTERVIEWS

Psychedeic-Chronicle-Logo

Psychedelic News - Page 2

Choose Ketamine Complete Seed Capital Raise to Expand Technology Platform Psychedeic-Chronicle-Logo-White
Psychedelic News

Choose Ketamine Complete Capital Raise to Expand Technology Platform

February 16, 2023

In a major milestone for mental health care, Austin-based Choose Your Horizon Inc., also known as Choose Ketamine, has announced the completion of its seed financing round. Led by Manifestations Capital in collaboration with Notley Ventures and numerous industry veterans and thought leaders, this

Read More
Biomind Labs Secure Pre-IND Meeting, Seek FDA Feedback on New Triptax Depression Treatment Psychedeic-Chronicle-Logo-White
Psychedelic News

Biomind Labs Secure FDA Pre-IND Meeting for Feedback on NCE Triptax

October 14, 2022

The well-known psychedelic biotech company Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) announced that it has been granted a Pre-Investigational New Drug (Pre-IND) meeting by the U.S. Food and Drug Administration (FDA) for new chemical entity Triptax™. Biomind Labs is devoted to crafting innovative pharmaceuticals for patients with neurological and psychiatric disorders, using

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment Psychedeic-Chronicle-Logo-White
October 10, 2022

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced today that

Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use Psychedeic-Chronicle-Logo-White
October 7, 2022

Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use

Numinus Wellness Inc.’s (OTCQX: NUMIF) (TSX: NUMI) research division, Numinus Bioscience, recently

Cybin-Announces-Dosing-of-First-Patients-in-Phase-1-2a-Clinical-Trial-of-CYB003-Psilocybin-Analog-for-Depression Psychedeic-Chronicle-Logo-White
Psychedelic News

Cybin Announces Dosing of First Patients in Phase 1/2a Clinical Trial of CYB003 Psilocybin Analog for Depression

Psychedelic biopharmaceutical company Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) announced today the dosing of the first two patients in the company’s Phase

August 30, 2022
Revitalist-and-Awakn-Life-Sciences-Announce-Licensing-Partnership-for-Ketamine-Assisted-Therapy-for-Alcohol-Use-Disorder Psychedeic-Chronicle-Logo-White
Psychedelic News

Revitalist and Awakn Life Sciences Announce Licensing Partnership for Ketamine-Assisted Therapy for Alcohol Use Disorder

One of the largest publicly listed ketamine focused clinic operations operating in the United States, Revitalist Lifestyle and Wellness Ltd. (CSE: CALM)

August 15, 2022
Small-Pharma-Receive-UK-Regulatory-Approval-to-Begin-DMT-Assisted-Psychotherapy-and-SSRI-Drug-Interaction-Study Psychedeic-Chronicle-Logo-White
Psychedelic News

Small Pharma Receive UK Regulatory Approval to Begin DMT-Assisted Psychotherapy and SSRI Drug Interaction Study

Psychedelic biotechnology company Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) announced today confirmation of regulatory approval from the U.K. Medicines and Healthcare

August 15, 2022
Short Wave Pharma Sign Clinical Trial Agreement with Sheba Research Fund & Sheba Center for Eating Disorders to Study Psilocybin Treatment for Anorexia Psychedeic-Chronicle-Logo-White
Psychedelic News

Short Wave Pharma Sign Clinical Trial Agreement with Sheba Research Fund & Sheba Center for Eating Disorders to Study Psilocybin Treatment for Anorexia

Biopharmaceutical company Short Wave Pharma Inc. has announced a signed Clinical Trial Agreement with the Sheba Fund for Health Services and Research. Dr. Eitan

August 15, 2022
Field-Trip-Health-Wellness-Announce-19-Million-Financing-To-Trade-on-TSXV-Under-Ticker-FTHW Psychedeic-Chronicle-Logo-White
Psychedelic News

Field Trip Health & Wellness Announce $19.9 Million Financing, Will Trade on TSXV Under Ticker FTHW

Field Trip Health & Wellness Ltd. announced today that the company has filed the necessary listing application to list its common shares

August 15, 2022
Silo-Pharma-Announce-Topically-Administered-Ketamine-Delivers-Positive-Results-in-Study Psychedeic-Chronicle-Logo-White
Psychedelic News

Silo Pharma Announce Topically Administered Ketamine Delivers Positive Results in Study

Silo Pharma, Inc. (OTCQB: SILO), a development-stage psychedelic biopharmaceutical firm, announced that the company’s patented topically applied ketamine formulation has completed a

August 2, 2022
Biomind Labs Hire Former FDA Director To Oversee Psychedelic Drug Development Clinical Trials Psychedeic-Chronicle-Logo-White
Psychedelic News

Biomind Labs Hire Former FDA Director To Oversee Psychedelic Drug Development Clinical Trials

World-class psychedelic biotech firm Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) announced that Former FDA Director Dr. Thomas Laughren has

August 1, 2022
Filament Health Join TheraPsil in Worlds Largest Medical Psilocybin Access and Data Project Psychedeic-Chronicle-Logo-White
Psychedelic News

Filament Health Join TheraPsil in World’s Largest Medical Psilocybin Access and Data Project

Clinical‐stage natural psychedelic drug development company Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) today announced the company’s participation in Project Solace, the

July 28, 2022
Wellbeing KGK Science Enters Phase II Clinical Trial Research Contract With Halucenex Psychedeic-Chronicle-Logo-White
Psychedelic News

Wellbeing’s KGK Science Enters Phase II Clinical Trial Research Contract With Halucenex

Evidence-based mental healthcare company Wellbeing Digital Sciences Inc. (NEO: MEDI) (OTC: KONEF) (FRA: SQ2) announced that its wholly-owned subsidiary KGK Science Inc. has entered into

July 22, 2022
Journey-Colab-Announces-Appointment-of-Joel-A-Posener-MD-as-Chief-Medical-Officer Psychedeic-Chronicle-Logo-White
Psychedelic News

Journey Colab Announces Appointment of Joel A. Posener, MD as Chief Medical Officer

Biopharmaceutical company Journey Colab who are working to unlock the science of psychedelics and build a new model for addiction treatment recently

July 20, 2022
Previous 1 2 3 Next

Recent Posts

  • Choose Ketamine Complete Capital Raise to Expand Technology Platform
  • Biomind Labs Secure FDA Pre-IND Meeting for Feedback on NCE Triptax
  • Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment
  • Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use
  • atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial

Recent Comments

No comments to show.

Popular

Choose Ketamine Complete Seed Capital Raise to Expand Technology Platform

Choose Ketamine Complete Capital Raise to Expand Technology Platform

In a major milestone for mental health care, Austin-based Choose

Biomind Labs Secure Pre-IND Meeting, Seek FDA Feedback on New Triptax Depression Treatment

Biomind Labs Secure FDA Pre-IND Meeting for Feedback on NCE Triptax

The well-known psychedelic biotech company Biomind Labs Inc. (NEO: BMND)

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced

Psychedeic-Chronicle-Logo

© 2022 PSYCHEDELIC CHRONICLE
ALL RIGHTS RESERVED.

  • Psychedelic News
  • DMT
  • Ketamine
  • Mescaline
  • Psilocybin
  • CEO INTERVIEWS